357 related articles for article (PubMed ID: 30917865)
1. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
2. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
3. TET2 binds the androgen receptor and loss is associated with prostate cancer.
Nickerson ML; Das S; Im KM; Turan S; Berndt SI; Li H; Lou H; Brodie SA; Billaud JN; Zhang T; Bouk AJ; Butcher D; Wang Z; Sun L; Misner K; Tan W; Esnakula A; Esposito D; Huang WY; Hoover RN; Tucker MA; Keller JR; Boland J; Brown K; Anderson SK; Moore LE; Isaacs WB; Chanock SJ; Yeager M; Dean M; Andresson T
Oncogene; 2017 Apr; 36(15):2172-2183. PubMed ID: 27819678
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of DNA epigenetic modulators during prostate carcinogenesis in an eastern Indian patient population: Prognostic implications.
Banerjee A; Bardhan A; Sarkar P; Datta C; Pal DK; Saha A; Ghosh A
Pathol Res Pract; 2024 Jan; 253():154970. PubMed ID: 38056136
[TBL] [Abstract][Full Text] [Related]
5. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
[TBL] [Abstract][Full Text] [Related]
6. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.
Devaney JM; Wang S; Funda S; Long J; Taghipour DJ; Tbaishat R; Furbert-Harris P; Ittmann M; Kwabi-Addo B
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):292-300. PubMed ID: 23896626
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
10. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
[TBL] [Abstract][Full Text] [Related]
11. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
12. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer.
Kim JW; Kim ST; Turner AR; Young T; Smith S; Liu W; Lindberg J; Egevad L; Gronberg H; Isaacs WB; Xu J
PLoS One; 2012; 7(10):e48455. PubMed ID: 23119026
[TBL] [Abstract][Full Text] [Related]
13. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
14. DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.
Cheong A; Zhang X; Cheung YY; Tang WY; Chen J; Ye SH; Medvedovic M; Leung YK; Prins GS; Ho SM
Epigenetics; 2016 Sep; 11(9):674-689. PubMed ID: 27415467
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
16. [Association of TET2, LMTK2 and FAM84B gene expression with prostate cancer risk in Chinese patients].
Wang NN; Wang JY; Shi XH; Zhang YG; Liu M; Wang X; Hui J; Chen X; Liang SY; Wei D; Yang F; Zhao F; Zhang YH; Yang Z
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):262-7. PubMed ID: 23985253
[TBL] [Abstract][Full Text] [Related]
17. A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
Kamdar S; Fleshner NE; Bapat B
BMC Cancer; 2020 Oct; 20(1):953. PubMed ID: 33008340
[TBL] [Abstract][Full Text] [Related]
18. Epigenome-wide DNA methylation and transcriptome profiling of localized and locally advanced prostate cancer: Uncovering new molecular markers.
Liu Q; Reed M; Zhu H; Cheng Y; Almeida J; Fruhbeck G; Ribeiro R; Hu P
Genomics; 2022 Sep; 114(5):110474. PubMed ID: 36057424
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
[TBL] [Abstract][Full Text] [Related]
20. Tet1 and Tet2 Protect DNA Methylation Canyons against Hypermethylation.
Wiehle L; Raddatz G; Musch T; Dawlaty MM; Jaenisch R; Lyko F; Breiling A
Mol Cell Biol; 2016 Feb; 36(3):452-61. PubMed ID: 26598602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
